Phio Pharmaceuticals Shares Surge on Positive Skin Cancer Trial Data
Phio Pharmaceuticals stock climbed nearly 10% premarket following encouraging safety and efficacy results from a Phase 1b skin cancer study. The company targets an FDA submission in the second quarter of 2026.
Technology
